Welcome to our dedicated page for Hutchmed (China) SEC filings (Ticker: HCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HUTCHMED (China) Limited filings document a foreign private issuer with American depositary shares linked to its ordinary-share capital. Form 6-K submissions furnish press releases, annual report materials, shareholder-meeting documents, total voting-rights notices, and governance disclosures for the company’s Nasdaq, AIM and HKEX-listed securities.
The filing record covers HUTCHMED’s targeted therapy and immunotherapy business, China regulatory updates, oncology and immunology pipeline disclosures, licensed product matters, and annual reporting. Other recurring filing subjects include AGM notices and proxy materials, voting instructions for American depositary share holders, long-term incentive plan award vesting, and capital-structure details for ordinary shares, depositary interests and ADSs.
HUTCHMED (China) Limited reported that long-term incentive awards granted on June 5, 2023 under its Long Term Incentive Plan have vested following the announcement of its 2025 annual results. On March 10, 2026, 524,079 ordinary shares vested to Dr Weiguo Su and 202,238 ordinary shares vested to Mr Johnny Cheng, totaling 726,317 shares.
These awards vested at nil price and relate to ordinary shares of US$0.10 each. Both executives are classified as persons discharging managerial responsibilities, and the transactions took place outside a trading venue, in line with UK Market Abuse Regulation notification requirements.
HUTCHMED (China) Ltd director Yang Ling filed an initial Form 3, formally reporting their beneficial ownership position as an insider of the company. The available data show no reported purchases, sales, acquisitions, or disposals of HUTCHMED securities in this filing.
HUTCHMED (China) Ltd director Daniel Shao Weng Tan filed an initial insider ownership report on Form 3. The filing lists him as a director of the company and does not report any insider buy, sell, acquisition, or disposition transactions at this time.
HUTCHMED (China) Ltd director Renu Bhatia has filed an initial Form 3 reporting her holdings in the company. The filing shows direct beneficial ownership of 16,000 ordinary shares following the reported position, with no specific buy or sell transaction indicated in this disclosure.
HUTCHMED (China) Ltd director Tony Shu Kam Mok filed an initial ownership report on Form 3. He reported beneficial ownership of 27,341 American depositary shares. Each American depositary share represents 5 ordinary shares of HUTCHMED.
HUTCHMED (China) Ltd director Wong Tak Wai has filed a Form 3, which is an initial statement of insider ownership. The filing lists him as a director but shows no share transactions and no reported buy, sell, acquire, or dispose activity at this time.
HUTCHMED (China) Ltd director Eldar Dan filed an initial ownership report listing his direct equity stake in the company. He reported holding 19,000 ordinary shares and 26,332 American depositary shares. A footnote states that each American depositary share represents 5 ordinary shares. The filing does not show any new buy or sell transactions, only existing holdings.
HUTCHMED (China) Ltd reported that Hu Chaohong is a director and a reporting person on a Form 3. The data provided shows no insider transactions, with zero shares listed as bought, sold, acquired, or disposed in this filing snapshot.
HUTCHMED (China) Ltd director Edith Shih has filed an initial ownership report showing her equity stake in the company. She reports direct holdings of 700,000 ordinary shares and 100,000 American depositary shares. Each American depositary share represents 5 ordinary shares.
HUTCHMED is withdrawing cancer drug TAZVERIK® from Greater China after safety concerns emerged in a major global study. Ipsen, which holds the marketing authorization, is voluntarily withdrawing TAZVERIK in the US following data from the SYMPHONY-1 trial showing secondary blood cancers that may outweigh benefits.
HUTCHMED’s subsidiary has begun market withdrawal and product recalls in the Chinese mainland, Hong Kong and Macau, and has stopped all active tazemetostat clinical trials locally. Healthcare providers and pharmacies have been told to cease prescribing and dispensing the drug, and trial sites must stop using it.
TAZVERIK had conditional approval in China for follicular lymphoma, with ongoing obligations tied to foreign safety signals. HUTCHMED reports that the withdrawal is not expected to affect its overall financial guidance; 2025 TAZVERIK sales were US$2.5 million.